After Ebola and Zika: Preparing for the Next Pandemic

Panel Composition and Context

• The panel included Anthony Banbury (UN Assistant Secretary General/Philanthropic Officer), Dara Erk (VP External Affairs, ARISE), Rajiv Ruiz (U.S. Representative, CA-36), and Rajiv Venkay (President, Global Vaccines Business, Takeda).
• The discussion focused on lessons from the 2014 Ebola outbreak, the immediate threat of Zika, and the strategic preparation for future pandemics.

Lessons from the Ebola Outbreak

• The primary failure of the Ebola response was the lack of prevention; the world had actionable information by March 2014 but failed to act until August 2014.
• The crisis highlighted a critical operational gap: the WHO sets policy but lacks the logistical capacity to deploy medical teams, creating ambiguity about who is responsible for containment.
• During the 2014 crisis, there was no single entity in charge of ending the epidemic, forcing the U.N. Secretary-General to assign the task to a non-expert, leading to a "build the plane while flying it" scenario.
• The U.S. response was complicated by jurisdictional confusion between federal, state, and local levels, a issue that persists globally.

Financing and Public-Private Partnerships

• A significant funding gap exists for diseases like Tuberculosis (TB), where 1.5 million die annually; the funding gap for TB vaccines is approximately $250 million per year.
• Panelists advocated for "push incentives" (public funding of R&D) over "pull incentives" (market guarantees) to de-risk high-consequence, low-probability investments for pharmaceutical companies.
• The Gates Foundation and similar entities are using "push funding" to cover R&D costs for companies like ARISE, allowing them to focus on development rather than capital allocation.
• Innovative financing models, such as the African Risk Capacity, utilize disaster risk insurance triggered by specific actuarial data to release funds before catastrophic economic impacts occur.
• Congressman Ruiz called for a specific $1.9 billion funding package for the Zika virus, arguing that Congress must lead rather than relying on private sector improvisation.

Risk Assessment and Prioritization

• Takeda and the U.S. government utilize a risk framework based on threat, population vulnerability, and consequences (lack of treatment/airborne transmission) to prioritize vaccine development.
• Potential next pandemics identified by the panel include:
  • Influenza strains capable of evading human immunity.
  • Hemorrhagic fever viruses and coronaviruses (MERS, SARS).
  • Vector-borne diseases including Zika, Chikungunya, and Dengue.
  • "Boring" diseases like measles, where outbreaks persist due to low vaccination awareness rather than cost.
• The highest probability for the next pandemic lies in resource-poor settings lacking diagnostic and containment infrastructure.

Regulatory and Operational Challenges

• While U.S. regulators (FDA) were praised for rapid Ebola response times, international deployment is hindered by a lack of coordinated global regulatory approval.
• A key barrier to fast-tracking vaccines is maintaining safety data for "healthy" populations to avoid eroding public trust in medical systems.
• The International Health Regulations (2006) require countries to report outbreaks within 24 hours, but economic fears (e.g., tourism loss) often discourage transparency.
• Corruption in vaccine distribution, particularly in urban slums, requires strict oversight, local partnership, and technological tracking to ensure equitable access.

Antimicrobial Resistance (AMR)

• No new classes of antibiotics for Gram-negative bacteria have been developed in 50 years; projections suggest a return to "pre-penicillin" mortality levels by 2050.
• Pharmaceutical companies lack financial incentives to develop antibiotics due to low ROI compared to chronic disease treatments (e.g., Lipitor).
• Panelists emphasized the need for responsible antibiotic use policies, such as banning routine antibiotic use in livestock, alongside public-private R&D partnerships.

Future Initiatives and Forward-Looking Statements

• The Coalition for Epidemic Preparedness Innovations (CEPI), a Davos-originated group, is operationalizing recommendations with three workstreams: R&D, organizational structure, and financing.
• CEPI expects to present concrete recommendations by the next World Economic Forum, backed by the Norwegian government, Wellcome Trust, and Gates Foundation.
• Panelists propose a global pandemic insurance mechanism where countries buy policies triggered by infection rates to enable rapid financial response.
• There is a consensus that future preparedness requires shifting from reactive crisis management to proactive infrastructure investment in community health and logistics.
• The panel stressed that "preventing" a pandemic is more effective than responding to one, requiring early investment in basic community health workers rather than high-tech labs.